drugset / Trial / NCT06232239

Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg

NCT06232239

Phase 1 Unknown 26 enrolled Bio-innova Co., Ltd
RandomizedCrossoverOpen-labelBasic science

Summary

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 7 days washout period between the doses.

Timeline

Start
2024-02-27
Primary completion
2024-04-05
Completion
2024-04-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 10 mg Oral

Indications

No indication recorded.